Johnson & Johnson

Telegraph Media Group | January 26, 2017

Johnson & Johnson is buying blood pressure specialist Actelion in an all-cash deal that values the company at $30bn (£23.8bn), following months of complex negotiation and marking the first big pharmaceuticals transaction of the year....

Johnson & Johnson | May 10, 2017

Johnson & Johnson is under investigation by US authorities over marketing, rebates and payment support programmes, according to documents filed with the financial regulator....

Johnson & Johnson (JNJ) | June 08, 2017

Johnson & Johnson (JNJ) appears to be planning some big moves with its pharma pipeline. The company reportedly hired Merck (MRK)’s Mathai Mammen to helm J&J’s research and development unit. Mammen will replace Bill Hait who is taking over the reins of external innovation at J&J, Endpoints first reported this morning. According to the Endpoints report, Mammen will join Johnson & Johnson later this month, then assume the reins of the R&D unit in 2018....

Johnson & Johnson | July 26, 2017

Johnson & Johnson has announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies. In an oral presentation of the early stage Phase 1/2a APPROACH study at the 9th IAS Conference on HIV Science (IAS 2017), the "mosaic"-based vaccine regimen from Janssen Vaccines & Prevention B.V. (Janssen) appeared to be well-tolerated and elicited HIV-1 antibody responses in 100% of healthy volunteers (n=393). "Finding a ...